Моксифлоксацин: роль и место в лечении внебольничной пневмонии у взрослых

1. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67: 71–9.
2. Wiemken TL, Peyrani P, Ramirez JA. Global changes in the epidemiology of community-acquired pneumonia. Semin Respir Crit Med 2012; 33: 213–9.
3. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134–41.
4. Rosón B, Carratalá J, Dorca J et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on basis of conventional admission criteria. Clin Infect Dis 2001; 33: 158–65.
5. Rodriguez A, Lisboa T, Blot S et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med 2009; 35: 430–8.
6. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. Клин. микробиология и антимикроб. химиотерапия. 2010; 12 (3): 186–226.
7. Naber K, Adam D. Expertengruppe der PEG. Einteilung der Fluorchinolone. Chemother J 1998; 7: 66–8.
8. File TM. Optimal treatment strategies for community-acquired pneumonia: non-responders to conventional regimens. Chemotherapy 2001; 47 (Suppl. 4): 11–8.
9. Mandell LA, Marrie TJ, Grossman RF et al. Summary of Canadian Guidelines for the Initial Management of Community-acquired Pneumonia: An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis 2000; 11: 237–48.
10. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–57.
11. Ruiz-González A, Falguera M, Nogués A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999; 106: 385–90.
12. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America and American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27–S72.
13. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24: 1052–9.
14. Vanderkooi OG, Low DE, Green K et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40: 1288–97.
15. Harwell JI, Brown RB. The drug-resistant pneumococcus: clinical relevance, therapy, and prevention. Chest 2000; 117: 530–41.
16. Yuan X, Liang BB, Wang R et al. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials. J Chemother 2012; 24: 257–67.
17. Fogarty C, Grossman C, Williams J et al. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia. Infect Med 1999; 16: 748–63.
18. Petitpretz P, Arvis P, Marel M et al. Oral moxifloxacin vs. high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001; 119: 185–95.
19. File TM Jr, Larsen LS, Fogarty CM et al. Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. Today’s Therapeutic Trends 2001; 19: 251–70.
20. Hoeffken G, Meyer HP, Winter J et al. The efficacy and safety of two oral moxifloxacin regimens (200 mg or 400 mg once daily for 10 days) compared to oral clarithromycin (500 mg twice daily for 10 days) in the treatment of community-acquired pneumonia. Respir Med 2001; 95: 553–64.
21. Finch R, Schurmann D, Collins O et al. Randomized controlled trial of sequential inravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746–54.
22. Jardim JR, Rico G, de la Roza C et al. A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: Resultas of a multicenter clinical trial. Archivos de Bronconeumologia 2003; 39: 387–93.
23. Torres A, Muir JF, Corris P et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003; 21: 135–43.
24. Katz E, Larsen LS, Fogarty CM et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 2004; 27: 395–405.
25. Welte T, Petermann W, Schurmann D et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41: 1697–705.
26. Portier H, Brambilla C, Garre M et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005; 24: 367–76.
27. Kobayashi H, Nobuki A, Yoshihito N et al. Phase IIIdouble-blind comparative study of BAY 12-8039 (moxifloxacin) versus levofloxacin in patients with community-acquired pneumonia. Jpn J Chemother 2005; 53: 27–46.
28. Xu S, Xiong S, Xu Y et al. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community-acquired pneumonia. J Huazhong Univ Sci Technology Med Sci 2006; 26: 421–4.
29. Anzueto A, Niederman MS, Pearle J et al. Community-acquired pmeumonia recovery in the elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73–81.
30. Torres A, Garau J, Arvis P et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study – a randomized clinical trial. Clin Infect Dis 2008; 46: 1499–509.
31. Lode H, Grossman C, Choudhri S et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med 2003; 97: 1134–42.
32. Wenisch C, Krause R, Szell M et al. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment. Infection 2006; 34: 190–5.
33. Ewig S, Hecker H, Suttorp N et al. Moxifloxacin monotherapy versus b-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia. J Infection 2011; 62: 218–25.
34. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011; 17 (Suppl. 6): 1–59.
35. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicology Letters 2002; 127: 269–77.
36. Kubin R, Reiter C. Safety update of moxifloxacin: a current review of clinical trials and post-marketing observational studies. 41st ICAAC, Sept. 2000; Abst 820.
37. Ball AP. The Quinolones – history and overview. In: The Quinolones, 3rd Edition. Ed VT Andriole. San Diego, USA. Academic Press 2001; Chap. 1.
38. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety. An analysis of 14 years of clinical data. Drugs R D 2012; 12: 71–100.

А.И.Синопальников

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава РФ, Москва